iSpecimen Inc. (ISPC) Operating Margin
- Operating margin · 12 months: Value -2020.04%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -2020.04% | Operating income / revenue. Period ending 2026-06-30. $-9.42M ÷ $466.30K × 100 ≈ -2020.04% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -9.42M USD | Operating Income (Loss) |
| Revenue | 466.30K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 971.13K USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-9.42M | $466.30K | $971.13K | (m) | (m) | -2020.04% |
| 2026-03-31 | $-9.88M | $1.03M | $1.33M | (m) | (m) | -961.36% |
| 2025-12-31 | $-8.98M | $1.93M | $1.90M | (m) | (m) | -465.42% |
| 2025-09-30 | $-12.13M | $3.35M | $2.63M | (m) | (m) | -361.81% |
| 2025-06-30 | $-11.01M | $5.91M | $3.98M | (m) | (m) | -186.28% |
| 2025-03-31 | $-11.37M | $8.06M | $4.96M | (m) | (m) | -141.04% |
| 2024-12-31 | $-12.73M | $9.29M | $5.30M | $1.49M | (m) | -136.99% |
| 2024-09-30 | $-9.76M | $10.39M | $5.41M | (m) | (m) | -93.92% |
| 2024-06-30 | $-10.25M | $10.51M | $5.24M | (m) | (m) | -97.53% |
| 2024-03-31 | $-11.63M | $9.27M | $4.67M | (m) | (m) | -125.46% |
| 2023-12-31 | $-11.17M | $9.93M | $4.82M | $1.62M | (m) | -112.50% |
| 2023-09-30 | $-10.44M | $10.31M | $4.80M | (m) | (m) | -101.21% |
| 2023-06-30 | $-11.35M | $10.12M | $4.59M | (m) | (m) | -112.12% |
| 2023-03-31 | $-10.37M | $10.83M | $4.74M | (m) | (m) | -95.72% |
| 2022-12-31 | $-10.19M | $10.40M | $4.76M | $1.47M | (m) | -97.92% |
| 2022-09-30 | $-10.04M | $9.99M | $4.57M | (m) | (m) | -100.50% |
| 2022-06-30 | $-8.40M | $10.12M | $4.30M | (m) | (m) | -82.94% |
| 2022-03-31 | $-7.34M | $10.69M | $4.79M | (m) | (m) | -68.67% |
| 2021-12-31 | $-5.93M | $11.14M | $5.25M | $295.31K | (m) | -53.21% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-2.41M | $8.18M | $3.59M | $319.24K | (m) | -29.40% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |